Cargando…
Assessment of the Evolution of Cancer Treatment Therapies
Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759197/ https://www.ncbi.nlm.nih.gov/pubmed/24212956 http://dx.doi.org/10.3390/cancers3033279 |
_version_ | 1782477222087491584 |
---|---|
author | Arruebo, Manuel Vilaboa, Nuria Sáez-Gutierrez, Berta Lambea, Julio Tres, Alejandro Valladares, Mónica González-Fernández, África |
author_facet | Arruebo, Manuel Vilaboa, Nuria Sáez-Gutierrez, Berta Lambea, Julio Tres, Alejandro Valladares, Mónica González-Fernández, África |
author_sort | Arruebo, Manuel |
collection | PubMed |
description | Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors, are the antitumor drugs and radiation that have been the treatment of choice in some instances. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. Nanotechnology has recently arrived on the scene, offering nanostructures as new therapeutic alternatives for controlled drug delivery, for combining imaging and treatment, applying hyperthermia, and providing directed target therapy, among others. These therapies can be applied either alone or in combination with other components (antibodies, peptides, folic acid, etc.). In addition, gene therapy is also offering promising new methods for treatment. Here, we present a review of the evolution of cancer treatments, starting with chemotherapy, surgery, radiation and immunotherapy, and moving on to the most promising cutting-edge therapies (gene therapy and nanomedicine). We offer an historical point of view that covers the arrival of these therapies to clinical practice and the market, and the promises and challenges they present. |
format | Online Article Text |
id | pubmed-3759197 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-37591972013-09-04 Assessment of the Evolution of Cancer Treatment Therapies Arruebo, Manuel Vilaboa, Nuria Sáez-Gutierrez, Berta Lambea, Julio Tres, Alejandro Valladares, Mónica González-Fernández, África Cancers (Basel) Review Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases. Within the therapeutic arsenal, alongside surgery in the case of solid tumors, are the antitumor drugs and radiation that have been the treatment of choice in some instances. In recent years, immunotherapy has become an important therapeutic alternative, and is now the first choice in many cases. Nanotechnology has recently arrived on the scene, offering nanostructures as new therapeutic alternatives for controlled drug delivery, for combining imaging and treatment, applying hyperthermia, and providing directed target therapy, among others. These therapies can be applied either alone or in combination with other components (antibodies, peptides, folic acid, etc.). In addition, gene therapy is also offering promising new methods for treatment. Here, we present a review of the evolution of cancer treatments, starting with chemotherapy, surgery, radiation and immunotherapy, and moving on to the most promising cutting-edge therapies (gene therapy and nanomedicine). We offer an historical point of view that covers the arrival of these therapies to clinical practice and the market, and the promises and challenges they present. Molecular Diversity Preservation International (MDPI) 2011-08-12 /pmc/articles/PMC3759197/ /pubmed/24212956 http://dx.doi.org/10.3390/cancers3033279 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Arruebo, Manuel Vilaboa, Nuria Sáez-Gutierrez, Berta Lambea, Julio Tres, Alejandro Valladares, Mónica González-Fernández, África Assessment of the Evolution of Cancer Treatment Therapies |
title | Assessment of the Evolution of Cancer Treatment Therapies |
title_full | Assessment of the Evolution of Cancer Treatment Therapies |
title_fullStr | Assessment of the Evolution of Cancer Treatment Therapies |
title_full_unstemmed | Assessment of the Evolution of Cancer Treatment Therapies |
title_short | Assessment of the Evolution of Cancer Treatment Therapies |
title_sort | assessment of the evolution of cancer treatment therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759197/ https://www.ncbi.nlm.nih.gov/pubmed/24212956 http://dx.doi.org/10.3390/cancers3033279 |
work_keys_str_mv | AT arruebomanuel assessmentoftheevolutionofcancertreatmenttherapies AT vilaboanuria assessmentoftheevolutionofcancertreatmenttherapies AT saezgutierrezberta assessmentoftheevolutionofcancertreatmenttherapies AT lambeajulio assessmentoftheevolutionofcancertreatmenttherapies AT tresalejandro assessmentoftheevolutionofcancertreatmenttherapies AT valladaresmonica assessmentoftheevolutionofcancertreatmenttherapies AT gonzalezfernandezafrica assessmentoftheevolutionofcancertreatmenttherapies |